Plasma lyso-Gb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes

被引：1
|
作者：
Nowak, Albina [1 ]
Mechtler, Thomas P. [2 ]
Desnick, Robert J. [3 ]
Kasper, David C. [4 ]
机构：
[1] Univ Zurich Hosp, Zurich, Switzerland
[2] Univ Hosp Zurich, Vienna, Austria
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] ARCHIMED Life Sci, Vienna, Austria
来源：
MOLECULAR GENETICS AND METABOLISM | 2017年 / 120卷 / 1-2期
关键词：
Biomarker; Fabry disease; Heterozygotes; LysoGb3; α-galactosidase deficiency;
D O I：
10.1016/j.ymgme.2016.11.262
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
253
引用
收藏
页码：S103 / S104
页数：2
相关论文
共 50 条
  • [1] LC-MS/MS analysis of plasma lyso-Gb3 in Fabry disease
    Boutin, Michel
    Gagnon, Rene
    Lavoie, Pamela
    Auray-Blais, Christiane
    CLINICA CHIMICA ACTA, 2012, 414 : 273 - 280
  • [2] How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?
    Auray-Blais, Christiane
    Ntwari, Aime
    Clarke, Joe T. R.
    Warnock, David G.
    Oliveira, Joao Paulo
    Young, Sarah P.
    Millington, David S.
    Bichet, Daniel G.
    Sirrs, Sandra
    West, Michael L.
    Casey, Robin
    Hwu, Wuh-Liang
    Keutzer, Joan M.
    Zhang, X. Kate
    Gagnon, Rene
    CLINICA CHIMICA ACTA, 2010, 411 (23-24) : 1906 - 1914
  • [3] Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy
    Hitoshi Sakuraba
    Tadayasu Togawa
    Takahiro Tsukimura
    Hiroshi Kato
    Clinical and Experimental Nephrology, 2018, 22 : 843 - 849
  • [4] Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy
    Sakuraba, Hitoshi
    Togawa, Tadayasu
    Tsukimura, Takahiro
    Kato, Hiroshi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2018, 22 (04) : 843 - 849
  • [5] A Metabolomic Study Reveals Novel Plasma Lyso-Gb3 Analogs As Fabry Disease Biomarkers
    Dupont, F. O.
    Gagnon, R.
    Boutin, M.
    Auray-Blais, C.
    CURRENT MEDICINAL CHEMISTRY, 2013, 20 (02) : 280 - 288
  • [6] Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb3) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
    Young-Gqamana, Brandy
    Brignol, Nastry
    Chang, Hui-Hwa
    Khanna, Richie
    Soska, Rebecca
    Fuller, Maria
    Sitaraman, Sheela A.
    Germain, Dominique P.
    Giugliani, Roberto
    Hughes, Derralynn A.
    Mehta, Atul
    Nicholls, Kathy
    Boudes, Pol
    Lockhart, David J.
    Valenzano, Kenneth J.
    Benjamin, Elfrida R.
    PLOS ONE, 2013, 8 (03):
  • [7] Characterization of Fabry disease-associated lyso-Gb3 on mouse colonic ion transport and motility
    Delprete, Cecilia
    Uhlig, Friederike
    Caprini, Marco
    Hyland, Niall P.
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2024, 327 (06): : G810 - G817
  • [8] Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis
    Maruyama, Hiroki
    Miyata, Kaori
    Mikame, Mariko
    Taguchi, Atsumi
    Guili, Chu
    Shimura, Masaru
    Murayama, Kei
    Inoue, Takeshi
    Yamamoto, Saori
    Sugimura, Koichiro
    Tamita, Koichi
    Kawasaki, Toshihiro
    Kajihara, Jun
    Onishi, Akifumi
    Sugiyama, Hitoshi
    Sakai, Teiko
    Murata, Ichijiro
    Oda, Takamasa
    Toyoda, Shigeru
    Hanawa, Kenichiro
    Fujimura, Takeo
    Ura, Shigehisa
    Matsumura, Mimiko
    Takano, Hideki
    Yamashita, Satoshi
    Matsukura, Gaku
    Tazawa, Ryushi
    Shiga, Tsuyoshi
    Ebato, Mio
    Satoh, Hiroshi
    Ishii, Satoshi
    GENETICS IN MEDICINE, 2019, 21 (01) : 44 - 52
  • [9] One-step synthesis of carbon-13-labeled globotriaosylsphingosine (lyso-Gb3), an internal standard for biomarker analysis of Fabry disease
    Hong, Xinying
    Gelb, Michael H.
    MOLECULAR GENETICS AND METABOLISM, 2018, 125 (03) : 292 - 294
  • [10] Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease
    Nowak, Albina
    Beuschlein, Felix
    Sivasubramaniam, Visnuka
    Kasper, David
    Warnock, David G.
    JOURNAL OF MEDICAL GENETICS, 2022, 59 (03) : 287 - 293
12345